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Abstract
Background: Decision-making about palliative care for metastatic colorectal cancer (mCRC) consists of many different
treatment-related decisions, and there generally is no best treatment option. Decision support systems (DSS),
e.g., prognostic calculators, can aid oncologists’ decision-making. DSS that contain features tailored to the needs of
oncologists are more likely to be implemented in clinical practice. Therefore, our aim is to inventory colorectal cancer
specialists’ unmet decision support needs.
Methods: We asked oncologists from the Dutch colorectal cancer group (DCCG), to participate in an online inventory
questionnaire on their unmet decision support needs. To get more in-depth insight in required features of the DSS
they need, we also conducted semi-structured telephone interviews.
Results: Forty-one oncologists started the inventory questionnaire, and 27 of them completed all items. Of all
respondents, 18 were surgeons (44%), 22 were medical oncologists (54%), and 28 (68%) had more than 10
years of experience treating mCRC. In both the inventory questionnaire and interviews, respondents expressed
a need for an overarching DSS incorporating multiple treatment options, and presenting both the treatment
benefits and harms. Respondents found it relevant for other outcomes, such as cost-effectiveness of treatment
or quality of life, to be incorporated in DSS. There was also a wish for DSS incorporating an up-to-date “personalized”
overview of the ongoing trials for which a specific patient is eligible.
Conclusions: Experienced oncologists indicate that their treatment advice is currently almost solely based on
the available clinical guidelines. They experience a lack of good quality DSS to help them personalize their
treatment advice. New tools integrating multiple treatment options and providing a broad range of clinically
relevant outcomes are urgently needed to stimulate and safeguard more personalized treatment decision-making.
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Background
Clinical decision-making about palliative treatment for
metastatic colorectal cancer (mCRC) is complex. The
patient population is heterogeneous in terms of type
of metastases and prognosis, and decision-making en-
compasses many decisions during the course of treat-
ment. The key premise of palliative treatment is to
maintain and/or improve patients’ quality of life. Clin-
ical guidelines give treatment options for the specific
stages of disease and are of a general nature. In this
era of personalized treatment, decision support sys-
tems (DSS), e.g., online prognostic calculators, deci-
sion trees and nomograms, can help oncologists to
better conceptualize the trade-off between treatment
benefits and harms for individual patients. These tools
can thereby help them to give a more personalized
evidence-based treatment advice to their patients, and
if adequately formatted DSS could be used during
consultations to inform patients.
Although DSS can be helpful, their usefulness de-
pends on their quality, whether their development was
methodologically sound, whether they have been ad-
equately externally validated, and which predictors
their estimates are based on. Currently, there is a lim-
ited number of DSS available for the mCRC setting
[1–11]. The majority of available tools have not been
externally validated, and for none of them a clinical
impact analysis has been performed [12]. Also, avail-
able DSS are mainly based on patient, tumor, and
treatment characteristics, and rarely include genetic
markers. Research into clinically important genetic
markers to aid further personalization of treatment
decision-making is currently ongoing. There is some
evidence that oncogenes (e.g., KRAS, BRAF or
PIK3CA), and tumor suppressor genes (e.g., APC,
TP53 or PTEN) yield clinically relevant information
that can help oncologists select patients who will
benefit from specific (targeted) treatments [13–17].
However, the available data is not yet at a stage that
these markers can be used in clinical practice. Further,
if DSS only provide information about the treatment
benefits, this can shift the focus away from the poten-
tial side-effects, and could thus impede adequate valu-
ation of the trade-off between the treatment benefits
and harms. Thus, DSS should incorporate information
on both the benefits and harms of treatment.
Good quality DSS to aid decision-making about pallia-
tive treatment for mCRC are not yet available. It begs the
question whether gastroenterologists, surgical and medical
oncologists have a need for decision support tools. There-
fore, we disseminated an online questionnaire to inventory
colorectal cancer specialists’ need for new DSS, and gain
insight into what features such new tools should have in
order to meet the existing clinical needs.
Methods
Online inventory questionnaire development and
dissemination
In the inventory questionnaire, colorectal cancer special-
ists (further labeled as oncologists) were asked to indi-
cate whether or not they have unmet decision support
needs, and if this was the case, they were asked to de-
scribe the requirements and characteristics of new DSS
they need using an open-ended question. With the in-
ventory questionnaire we also assessed respondent char-
acteristics, namely a) type of hospital they work at, b)
number of years of experience treating patients with
mCRC, c) number of mCRC patients treated on a yearly
basis, d) which DSS for palliative treatment decisions in
patients with mCRC they are familiar with and utilize,
and e) which factors oncologists consider in order to
reach their treatment advise. All questions pertaining to
respondent characteristics were multiple choice includ-
ing the option ‘other’, with space to give another answer.
The inventory questionnaire was developed by the re-
search team that included clinical (CJAP) and palliative
care (BDOP) experts.
A link to the online inventory questionnaire was sent
to surgical, radiation, and medical oncologists who are
members of the Dutch colorectal cancer group (DCCG;
N = 360 members) via the DCCG secretariat.
DCCG-members are experts in the field of colorectal
cancer (CRC) diagnosis and treatment. The DCCG is a
working party in which healthcare professionals from
across the Netherlands specializing in colorectal cancer
take part. Participants’ did not receive compensation for
participation. Three weeks after the original invitation to
participate, a reminder was sent.
Individual interviews
With the inventory questionnaire we were unable to
delve deeply into respondents’ existing unmet decision
support needs. Therefore, we also conducted semi-struc-
tured individual telephone interviews. The interviewer
had a topic list (i.e., use of DSS, clinical situation for
which DSS are useful, unmet decision support needs)
that needed to be addressed, but any other topics raised
by the interviewee would also be explored. Respondents
provided us with contact information in the inventory
questionnaire if they were willing to participate in these
interviews. All interviews were audiotaped.
Data analyses
Descriptive analyses were performed on the inventory
questionnaire data. One of the in total 42 respondents
indicated not to have any experience with palliative care
for mCRC, and was excluded from all analyses. In order
to identify key points in the audio recordings of the in-
terviews, the interviewer (EGE) performed a thematic
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assessment of all answers. Themes from the interviews
were integrated with information from the online inven-
tory questionnaires to formulate the unmet needs.
Results
Population characteristics
Forty-one oncologists with experience treating mCRC
started the inventory questionnaire and 27 of them com-
pleted it. Respondents were mainly medical oncologists
(n = 22) and surgeons (n = 18) working at general teach-
ing hospitals (n = 25), and general hospitals (n = 10)
(Table 1). Of the oncologists, 68% had more than 10
years of experience treating patients with incurable
mCRC, and 57% saw between 11 and 50 incurable
mCRC patients per year. Four out of the nine oncolo-
gists who indicated in the inventory questionnaire that
they would be willing to be interviewed could be reached
for an interview. Three of them were medical oncolo-
gists, and one was a surgeon, and they regularly treated
patients with incurable mCRC.
In the questionnaire almost all respondents indi-
cated that they mainly used the Dutch national CRC
guidelines [18] and/or the national palliative care
guidelines [19] to guide their decision-making, and re-
spondents’ familiarity with and use of existing DSS
was limited. For example, only four out of 41
oncologists knew the nomogram developed by Fendler
et al. [4] 4, that predicts the probability of 1-year sur-
vival for mCRC patients with inoperable liver metasta-
ses after treatment with selective internal radiation
therapy (SIRT) (Table 2). One of these oncologists also
used this nomogram in clinical practice to inform
their own decision-making. Oncologists were not fa-
miliar with any other DSS for this setting. Figure 1
provides an overview of the importance specialists
give to patient and disease characteristics when devis-
ing their treatment advice in the context of mCRC
(questionnaire data).
Unmet decision support needs
In the inventory questionnaire, 28 oncologists indicated
that they had unmet needs for decision support, thus re-
quiring the development of a new DSS for mCRC treat-
ment decisions. Thirteen of them wanted a new DSS to
support their own decision-making, whilst eight wanted
a new DSS to support shared decision-making in clinical
practice. Figure 2 provides a summary of the unmet de-
cision support needs oncologists indicated in the inven-
tory questionnaire combined with qualitative data
obtained in the interviews.
During the interviews the most recurrent theme was
integration. First, integration of the available national
guidelines, as currently the colorectal cancer guideline
and palliative care guidelines are separate documents lo-
cated on two different websites. Respondents indicated
that with respect to the guidelines, it would be helpful if
the guidelines were supplemented with decision trees to
facilitate their use in clinical practice. Second, currently
available DSS only provide information about one out-
come or treatment option, i.e., expected survival with/
without a specific chemotherapy regimen or the prob-
ability of experiencing a specific side-effect. DSS need to
integrate multiple treatment options (e.g., head-to-head
comparison of various chemotherapy regimens or surgi-
cal vs. radiological treatment) for them to be most ef-
fective in clinical practice. Third, tools must present
both the benefits and harms of treatment. Preferably, a
tool incorporating the first three requirements also fea-
tures other outcomes, e.g., cost-effectiveness of treat-
ment, and presents a personalized overview of ongoing
trials for which patients with the selected characteristics
are eligible. Ideally, newly developed DSS with good dis-
criminatory ability and good calibration are incorporated
in the national guidelines, thereby facilitating their em-
bedding in clinical practice. Another unmet need identi-
fied in the interviews, was the need for informatics
solutions facilitating communication between intramural
and extramural health care providers. General practi-
tioners or community nurses generally know patients for
a long time and have better insight in patients’
Table 1 Characteristics of participants
Respondents inventory
questionnaire
N = 41 (100%)
Medical specialty
Surgeon 18 (44)
Medical oncologist 22 (54)
Gastroenterologist 1 (2)
Type of hospital
General hospital 9 (22)
General teaching hospital 25 (61)
University medical center 6 (15)
Specialized oncology hospital 1 (2)
Experience treating patients with incurable CRC
≤ 2 years 1 (2)
3–5 years 6 (15)
6–10 years 6 (15)
> 10 years 28 (68)
Number of patients treated on a yearly basis
0–5 patients 3 (7)
6–10 patients 6 (15)
11–20 patients 15 (37)
21–50 patients 9 (22)
> 50 patients 8 (20)
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(n = 31 responders)
Not familiar with any DSS 27
Familiar with SPICT 0
Familiar with the nomogram developed by Fendler et al.b 4
DSS use in clinical practice
(n = 21 responders)
Nomogram developed by Fendler et al.b 1
DSS decision support systems, SPICT Supportive and palliative care indicators tool
aNumbers do not add up to 41 due to missing data or because respondents could provide multiple answers
bThe Fendler et al. nomogram aims to help decision making about whether selective internal radiation therapy (SIRT) is indicated for hepatic metastases of
colorectal cancer. Predictions are based on 4 factors, namely: no liver surgery before SIRT, CEA serum level, transaminase toxicity level, and summed computed
tomography (CT) size of the largest two liver lesions4
Fig. 1 Overview of factors considered by medical specialists to inform their mCRC treatment advice (N = 32)
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circumstances. More efficient and thorough exchange of
patient information could aid oncologists in hospitals to
better estimate patients’ performance status for example.
Finally, although oncologists expressed a clear need for
DSS, they also conveyed a sense that such tools are not
meant to replace clinical judgement, only provide sup-
port: cookbook medicine is not desirable.
Discussion
We investigated whether oncologists currently have un-
met decision support needs in the context of palliative
treatment decision-making for mCRC. We found that on-
cologists that participated in our inventory questionnaire
only knew one DSS for decision-making about palliative
care for mCRC, namely the Fendler et al. [4] 4 nomogram.
However, currently good quality DSS to guide palliative
treatment decision-making for mCRC are lacking [12].
Available DSS have several shortcomings that limit their
relevance for clinical practice. The methodology used for
the development of DSS is not always optimal and often
they have not been adequately externally validated or have
only undergone narrow validations (e.g., in a single setting
or ethnic population) [2, 5]. Additionally, available tools
do not meet oncologists’ need for a comprehensive tool.
Available DSS do not compare both the pros and cons of
multiple treatment options, nor do they present relevant
ongoing trials, and additional non-clinical outcomes such
as cost-effectiveness of treatment options. Another short-
coming of available DSS is that they do not incorporate all
clinically relevant predictors, such as the treatment’s
impact on quality of life, the side-effects of treatment,
performance status and prognosis. Finally, using
informatics solutions facilitating communication between
intra- and extramural specialists could also facilitate deci-
sion-making. Better exchange of information between
healthcare providers contributes to the quality of care in
general. However, better information exchange could for
example, also improve the accuracy of the assessment of
patients’ performance status, which in turn would im-
prove estimates from prediction tools incorporating per-
formance status as a predictor. Given the meager offerings
in terms of available DSS, it is perhaps not surprising that
respondents have many unmet decision support needs.
Respondents indicated that they currently mainly
used the national CRC treatment guidelines [18] and/
or the national palliative care guidelines [19] to sup-
port their clinical decisions. Even though respondents
are confident in the quality of the content of the clin-
ical guidelines, their general nature means they can-
not be used to personalize treatment advice. One of
the needs expressed was the incorporation of clear
decision trees and good quality prediction tools in the
online platform where guidelines are located. This
would facilitate the embedding of DSS in the clinical
decision-making process.
Further, in spite of the growing evidence that some
oncogenes (e.g., KRAS, BRAF or PIK3CA), and tumor
suppressor genes (e.g., APC, TP53 or PTEN) are relevant
to prognosis, and could help to personalize treatment se-
lection [13–17], respondents indicated that they cur-
rently do not consider genetic markers when pondering
about their treatment advice. This is perhaps not
Fig. 2 Medical specialists’ unmet decision support needs with regards to mCRC treatment decisions (based on survey and interview data)
Engelhardt et al. BMC Medical Informatics and Decision Making          (2018) 18:132 Page 5 of 7
surprising as for the mCRC setting more evidence is
needed for such markers to be used in daily clinical
practice. Given the rapid progress being made in the
field of genetic markers and their potential to aid (fur-
ther) personalization of treatment selection in the future,
it is important that such factors are also incorporated in
future DSS (once their prognostic value has been
established).
If good quality DSS were available, they could help on-
cologists weigh the benefits and harms of treatment,
when deliberating about their mCRC treatment advice.
DSS, if they have a suitable patient interface, could also
help oncologists to inform their patients about the bene-
fits and harms of treatment. Given these potential bene-
fits, it is pivotal to identify the mCRC treatment
decisions for which oncologists have a need for decision
support. In our study we focused on this element. A
strength of our study is that we had access to all oncolo-
gists who are a member of the DCCG. Although the
number of respondents is modest, it is likely that the
specialists who participated are very experienced oncolo-
gists who use and/or feel a need for DSS in their daily
practice. As in this study we aimed to inventory the re-
quirements and characteristics of new DSS they need,
this makes our sample of oncologists valuable.
Given the complex and multi-faceted nature of pallia-
tive treatment decision-making, and the need for a per-
sonalized and patient-centered approach, it is somewhat
surprising that there are so few good quality DSS avail-
able for the mCRC setting. The development of new
DSS for the mCRC setting could be of great value to
clinical practice. However, development of new DSS
meeting specialists’ needs is not straightforward. More
research is needed to identify relevant predictors. This is
particularly the case for genetic markers to help in the
selection of patients for treatment. It is thus unlikely
that in the short-term a good quality DSS incorporating
genetic markers will be developed. In the meantime,
DSS estimating prognosis based on patient and disease
characteristics are more feasible and could nonetheless
be of added value to clinical practice (for example the
mortality calculator proposed by Refro et al. [20]). Fur-
ther, making DSS available that remain relevant and reli-
able in the long-term is a key consideration from a
methodological standpoint. For any (newly developed)
DSS to be useful in clinical practice in the long-term, it
is important that the tool is continuously updated. We
propose for example, embedding DSS in national patient
registries, to facilitate updating as new insights and
treatments become available. Finally, although DSS can
be of great value in clinical practice and oncologists
expressed a clear need for such tools, they also strongly
felt that DSS are nor should be a replacement for their
clinical judgement or for deliberation with patients.
Conclusion
Our sample of oncologists with ample experience
treating patients with mCRC indicated that many of
their decision support needs are currently not met.
Consequently, their treatment advice is almost solely
based on the available clinical guidelines. This limits
their ability to formulate more personalized treatment
advice based on objective estimates of relevant clinical
outcomes. New tools integrating multiple treatment
options and providing a broad range of clinically relevant
outcomes are urgently needed to stimulate personalization
of treatment advice and safeguard patient-centered treat-
ment decision-making.
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